Population-based active surveillance of pertussis hospitalization rates in two cities of China

中国两座城市百日咳住院率的基于人群的主动监测

阅读:1

Abstract

PURPOSE: Hospitalization is most common for severe pertussis cases and those with serious complications caused by pertussis. In mainland China, the immunization program consists of primary vaccinations at 3, 4, and 5 months, followed by a booster at 18 months with DTaP. It remains uncertain whether the first dose at 3 months, rather than 6 weeks as WHO recommended, may increase disease burden, as delayed immunization may lead to lagged protection. This study aimed to determine pertussis hospitalization rates by active surveillance in China, shedding light on immunization strategies for better disease control. METHODS: From June 1, 2021, to May 31, 2022, two Chinese cities underwent a population-based active surveillance. Suspected pertussis cases were confirmed as pertussis cases through PCR and culture. Pertussis hospitalization rates were calculated by dividing the number of laboratory confirmed pertussis cases by the hospitalization coverage rate of surveillance hospitals and the resident population. RESULTS: During the study period 2021-2022, pertussis hospitalization rate in Yiwu was 2.50/100,000 (95% CrI 2.48-2.53), while in Yongcheng, it was 7.90/100,000 (95% CrI 7.81-8.00). In both cities, infants aged < 1 year had the highest hospitalization rate (215.64/100,000: Yiwu; 217.65/100,000: Yongcheng), followed by the age group of 4-5 years (16.37/100,000: Yiwu; 65.70/100,000: Yongcheng). CONCLUSIONS: This study revealed significant pertussis hospitalization rates in China, particularly among infants aged < 1 year, highlighting the need of timely and early immunization. The higher hospitalization rates in the 4-5-year age group emphasize the importance of targeted preventive measures for preschool children to mitigate the impact of pertussis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。